Seres Therapeutics(CH:MCRB)
CH:MCRB
Seres Therapeutics financials statements
Seres Therapeutics (MCRB) Ratios
0 Followers
Seres Therapeutics Ratios
CH:MCRB's free cash flow for Q3 2026 was $-10.48M. For the 2026 fiscal year, CH:MCRB's free cash flow was increased by $0.00 and operating cash flow was $-10.48M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 |
| Quick Ratio | 2.56 | 0.94 | 1.48 | 2.28 | 3.69 |
| Cash Ratio | 2.37 | 0.75 | 1.30 | 1.90 | 2.19 |
| Solvency Ratio | 0.10 | -1.12 | -0.27 | -0.72 | -0.27 |
| Operating Cash Flow Ratio | 0.06 | -3.61 | -1.19 | -2.67 | 0.08 |
| Short-Term Operating Cash Flow Coverage | 0.11 | 0.00 | 0.00 | -501.79 | 0.00 |
| Net Current Asset Value | $ -44.60M | $ -87.35M | $ -228.05M | $ -143.24M | $ 80.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.60 | 0.66 | 0.55 | 0.47 | 0.14 |
| Debt-to-Equity Ratio | 1.88 | 6.65 | -4.43 | 15.08 | 0.37 |
| Debt-to-Capital Ratio | 0.65 | 0.87 | 1.29 | 0.94 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 1.79 | 0.82 | 0.16 |
| Financial Leverage Ratio | 3.13 | 10.14 | -7.99 | 32.35 | 2.70 |
| Debt Service Coverage Ratio | 0.95 | 0.00 | -13.77 | -26.39 | -19.49 |
| Interest Coverage Ratio | 0.00 | 0.00 | -14.81 | -29.89 | -22.16 |
| Debt to Market Cap | 0.08 | 0.00 | 0.57 | 0.08 | 0.03 |
| Interest Debt Per Share | 9.37 | 11.79 | 33.12 | 31.20 | 11.37 |
| Net Debt to EBITDA | 3.78 | -0.51 | -0.39 | 0.00 | 2.31 |
| Profitability Margins | |||||
| Gross Profit Margin | -423.83% | 0.00% | 0.00% | 0.00% | 100.00% |
| EBIT Margin | 721.93% | 0.00% | 0.00% | 0.00% | -43.24% |
| EBITDA Margin | 1245.75% | 0.00% | 0.00% | 0.00% | -39.14% |
| Operating Profit Margin | -11910.14% | 0.00% | 0.00% | 0.00% | -44.50% |
| Pretax Profit Margin | 721.93% | 0.00% | 0.00% | 0.00% | -45.25% |
| Net Profit Margin | 721.93% | 0.00% | 0.00% | 0.00% | -45.25% |
| Continuous Operations Profit Margin | 721.93% | 0.00% | 0.00% | 0.00% | -45.25% |
| Net Income Per EBT | 100.00% | 116.54% | 59.81% | 136.27% | 100.00% |
| EBT Per EBIT | -6.06% | 103.67% | 97.45% | 102.04% | 101.68% |
| Return on Assets (ROA) | 4.12% | -104.84% | -31.71% | -71.72% | -18.48% |
| Return on Equity (ROE) | 12.88% | -1063.34% | 253.53% | -2319.92% | -49.87% |
| Return on Capital Employed (ROCE) | -79.05% | -123.05% | -75.05% | -68.36% | -23.66% |
| Return on Invested Capital (ROIC) | -72.70% | -113.10% | -73.48% | -67.32% | -23.10% |
| Return on Tangible Assets | 4.12% | -104.84% | -31.71% | -71.72% | -18.48% |
| Earnings Yield | 4.32% | -113.50% | -63.46% | -41.33% | -8.58% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.46 | 0.87 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 4.01 |
| Asset Turnover | 0.01 | 0.00 | 0.00 | 0.00 | 0.41 |
| Working Capital Turnover Ratio | 0.06 | 0.00 | 0.00 | 0.00 | 0.65 |
| Cash Conversion Cycle | 18.00 | -421.53 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 166.54 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 148.54 | 421.53 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 166.54 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.13 | -19.13 | -18.34 | -42.34 | 1.46 |
| Free Cash Flow Per Share | 0.10 | -19.17 | -19.58 | -44.16 | -0.63 |
| Dividend Paid and CapEx Coverage Ratio | 4.43 | -391.08 | -14.72 | -23.30 | 0.70 |
| Capital Expenditure Coverage Ratio | 4.43 | -391.08 | -14.72 | -23.30 | 0.70 |
| Operating Cash Flow Coverage Ratio | 0.01 | -1.62 | -0.59 | -1.41 | 0.14 |
| Operating Cash Flow to Sales Ratio | 1.42 | 0.00 | 0.00 | 0.00 | 0.05 |
| Free Cash Flow Yield | 0.66% | -115.37% | -69.94% | -39.43% | -0.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 23.25 | -0.88 | -1.58 | -2.42 | -11.65 |
| Price-to-Sales (P/S) Ratio | 167.07 | 0.00 | 0.00 | 0.00 | 5.27 |
| Price-to-Book (P/B) Ratio | 2.98 | 9.37 | -4.00 | 56.13 | 5.81 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 152.39 | -0.87 | -1.43 | -2.54 | -265.42 |
| Price-to-Operating Cash Flow Ratio | 118.01 | -0.87 | -1.53 | -2.65 | 114.22 |
| Price-to-Earnings Growth (PEG) Ratio | -0.22 | -0.14 | 0.03 | -0.01 | 0.32 |
| Enterprise Value Multiple | 17.20 | -1.58 | -1.38 | -3.54 | -11.16 |
| Enterprise Value | 169.02M | 189.99M | 250.02M | 604.79M | 633.09M |
| EV to EBITDA | 17.20 | -1.58 | -1.38 | -3.54 | -11.16 |
| EV to Sales | 214.22 | 0.00 | 0.00 | 0.00 | 4.37 |
| EV to Free Cash Flow | 195.40 | -1.28 | -1.99 | -2.53 | -219.98 |
| EV to Operating Cash Flow | 151.32 | -1.28 | -2.13 | -2.64 | 94.66 |
| Tangible Book Value Per Share | 4.99 | 1.77 | -7.01 | 2.00 | 28.68 |
| Shareholders’ Equity Per Share | 4.99 | 1.77 | -7.01 | 2.00 | 28.68 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.09 | 0.00 | 0.00 | 0.00 | 31.61 |
| Net Income Per Share | 0.64 | -18.86 | -17.77 | -46.29 | -14.30 |
| Tax Burden | 1.00 | 1.17 | 0.60 | 1.36 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.01 | 1.03 | 1.05 |
| Research & Development to Revenue | 62.18 | 0.00 | 0.00 | 0.00 | 0.98 |
| SG&A to Revenue | 49.63 | 0.00 | 0.00 | 0.00 | 0.48 |
| Stock-Based Compensation to Revenue | 13.74 | 0.00 | 0.00 | 0.00 | 0.14 |
| Income Quality | 0.20 | -1092.71 | 1.03 | 0.91 | -0.10 |
Currency in USD

